U.S. Markets closed
  • S&P 500

    4,455.48
    +6.50 (+0.15%)
     
  • Dow 30

    34,798.00
    +33.18 (+0.10%)
     
  • Nasdaq

    15,047.70
    -4.54 (-0.03%)
     
  • Russell 2000

    2,248.07
    -10.97 (-0.49%)
     
  • Crude Oil

    73.95
    +0.65 (+0.89%)
     
  • Gold

    1,750.60
    +0.80 (+0.05%)
     
  • Silver

    22.37
    -0.27 (-1.20%)
     
  • EUR/USD

    1.1718
    -0.0029 (-0.25%)
     
  • 10-Yr Bond

    1.4600
    +0.0500 (+3.55%)
     
  • GBP/USD

    1.3681
    -0.0040 (-0.29%)
     
  • USD/JPY

    110.6850
    +0.3840 (+0.35%)
     
  • BTC-USD

    43,217.07
    +679.07 (+1.60%)
     
  • CMC Crypto 200

    1,067.20
    -35.86 (-3.25%)
     
  • FTSE 100

    7,051.48
    -26.87 (-0.38%)
     
  • Nikkei 225

    30,248.81
    +609.41 (+2.06%)
     

Three Analysts Initiate Coverage On This Newly Listed Precision Oncology Firm

·1 min read
  • Wedbush initiated coverage of Tango Therapeutics Inc (NASDAQ: TNGX) with an Outperform rating and a $12 price target.

  • Analyst Robert Driscoll believes Tango's unique synthetic lethality approach is differentiated.

  • Furthermore, he expects Tango to leverage this comprehensive platform to drive the discovery and development of many programs that lead to significant value creation.

  • Goldman Sachs initiated coverage of Tango Therapeutics with a Buy rating and a $17 price target.

  • Analyst Chris Shibutani believes Tango is "strongly positioned" as a precision oncology company.

  • The Company's proprietary drug discovery platform utilizes a synthetic lethality-based approach that addresses the "vast, largely untapped realm" of cancers driven by tumor suppressor gene loss, Shibutani tells investors in a research note.

  • Guggenheim initiated coverage of Tango Therapeutics with a Buy rating and a $16 price target.

  • Tango started trading on NASDAQ a couple of weeks back.

  • Its lead program TNG908 is a protein arginine methyl transferase 5 (PRMT5) inhibitor that is synthetic lethal with MTAP deletion.

  • IND submission for human trials is expected in Q4 of 2021.

  • Price Action: TNGX shares are up 15.2% at $14.89 during the market session on the last check Tuesday.

Latest Ratings for TNGX

Sep 2021

Wedbush

Initiates Coverage On

Outperform

Sep 2021

Guggenheim

Initiates Coverage On

Buy

Sep 2021

Goldman Sachs

Initiates Coverage On

Buy

View More Analyst Ratings for TNGX
View the Latest Analyst Ratings

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.